A biological hypothesis tested against placebo
Inflammation involving neutrophils, a type of white blood cell, is common in COPD. Mitiperstat inhibits myeloperoxidase, an enzyme expressed by these cells. This target represented a therapeutic hypothesis, not proof of efficacy.
The CRESCENDO trial included 381 adults aged 40 to 80 with moderate to severe COPD and a high risk of exacerbation. All were already receiving dual or triple inhaled therapy.
Participants were randomly assigned to mitiperstat or placebo, under double-blind conditions, for up to 24 weeks. The primary endpoint was the time to a first event meeting the COPDCompEx composite endpoint. A detailed definition of this endpoint is not provided in the excerpt reviewed.
No demonstrated improvement in the outcomes studied
A COPDCompEx event occurred in 66.1% of participants receiving mitiperstat, compared with 65.1% receiving placebo. Treatment did not prolong the time to this first event: the hazard ratio was 1.07, with a 90% confidence interval of 0.87 to 1.32.
No benefit was observed in the time to a first moderate to severe exacerbation either. The abstract reports no improvement in lung function, respiratory symptoms or disease impact.
These results do not demonstrate that every strategy targeting this inflammation is ineffective. They indicate that mitiperstat, under the conditions of this trial and in these patients already receiving treatment, did not deliver the intended benefit.
A safety signal to interpret with caution
The proportion of participants reporting adverse events was similar between groups. However, seven participants receiving mitiperstat developed pneumonia, compared with two receiving placebo.
This imbalance warrants attention, but the abstract alone does not establish its cause or quantify the statistical uncertainty. The authors conclude that the risks outweigh the benefits of mitiperstat as a treatment for COPD.
Limitations to keep in mind
Analysis based solely on the PubMed abstract provided, without consulting the full text. The results concern adults with moderate to severe COPD, at high risk of exacerbation and already receiving inhaled treatment, followed for up to 24 weeks. Funding, conflicts of interest and regulatory status in France or the European Union were not verified.
What we can take away
This trial does not support the use of mitiperstat in the COPD population studied. A plausible inflammatory target does not guarantee a clinical benefit.
Sources and provenance
- A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with COPD.
Source date: 2026-11-05.
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Multicenter Study · Résumé PubMed uniquement, texte intégral non consulté